



Jazz Pharmaceuticals to Report 2014 Fourth Quarter and Full Year Financial Results on February 24, 2015

February 10, 2015

DUBLIN, Feb. 10, 2015 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2014 fourth quarter and full year financial results on Tuesday, February 24, 2015, after the close of the financial markets. Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EST/9:30 p.m. GMT to discuss fourth quarter and full year 2014 financial results and provide a business and financial update and guidance for 2015 financial results.

Interested parties may access the live audio webcast via the Investors & Media section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary to listen to the webcast. A replay of the webcast will be archived on the website for one week.

Audio webcast/conference call:

U.S. Dial-In Number: +1 800 237 9752

International Dial-In Number: +1 617 847 8706

Passcode: 21347754

A replay of the conference call will be available through March 3, 2015 and accessible through one of the following telephone numbers, using the passcode below:

Replay U.S. Dial-In Number: +1 888 286 8010

Replay International Dial-In Number: +1 617 801 6888

Passcode: 39765339

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is an international biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing meaningful products that address unmet medical needs. The company has a diverse portfolio of products and/or product candidates with a focus in the areas of sleep and hematology/oncology. In these areas, Jazz Pharmaceuticals markets Xyrem® (sodium oxybate) oral solution and Erwinaze® (asparaginase *Erwinia chrysanthemi*) in the U.S., and markets Erwinase® and Defitelio® (defibrotide) in Europe and other countries outside the U.S. For more information, please visit www.jazzpharmaceuticals.com.

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-report-2014-fourth-quarter-and-full-year-financial-results-on-february-24-2015-300033967.html>

SOURCE Jazz Pharmaceuticals plc

Investors, Kathee Littrell, Vice President, Investor Relations, Ireland, +353 1 634 7887, U.S., +1 650 496 2717, or Media, Laurie Hurley, Vice President, Corporate Affairs, Ireland, +353 1 634 7894, U.S., +1 650 496 2796